Trial Profile
A phase II study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Sargramostim
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Apr 2013 Planned end date changed from 1 Jul 2012 to 1 Jan 2023 as reported by ClinicalTrials.gov.
- 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Bavarian Nordic media release. Results were also briefly summarised in the media release.